GAPDH and familial pancreatic carcinoma: Furthermore, the capability of AXP-3019 to synergistically inhibit PDAC cell proliferation in drug-combination studies, with the standard chemotherapeutic drug gemcitabine, supports the assumption that the glycolytic enzyme GAPDH may represent an effective therapeutic target for new interventions in pancreatic-cancer cells.